Detail

Study ID: Merck MK7902-001

Title:

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma

Description:
Title: A Phase 3, Randomized, Open-label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/ MK-7902) Versus Chemotherapy for First-Line Treatment of Advaned or Recurrent Endometrial Carcinoma (LEAP-001) Description: The purpose of this study is to compare the effectiveness of Merck study drugs to FDA approved treatment in women with advanced or recurrent endometrial carcinoma. It is our thought that the combination of the study drugs will be better for progression-free survival. It is also our thought that the combination of the study drugs will be better for overall survival than the drugs already approved by the FDA.
Location:
Fargo Region, Sioux Falls Region
Principal Investigator:
Maria Bell, MD
Disease:
Uterus
Stage:
Phase III
Status:
Active - Open to Accrual